miR-545 inhibited pancreatic ductal adenocarcinoma growth by targeting RIG-I

被引:49
|
作者
Song, Bin [1 ]
Ji, Weiping [1 ]
Gu, Shiwei [1 ]
Liu, Anan [1 ]
Jing, Wei [1 ]
Shao, Chenghao [1 ]
Li, Gang [1 ]
Jin, Gang [1 ]
机构
[1] Second Mil Med Univ, Dept Pancreat Surg, Changhai Hosp, Shanghai 200082, Peoples R China
基金
上海市自然科学基金;
关键词
miR-545; Pancreatic ductal adenocarcinoma; RIG-I; Patients survival; Cancer growth; HEPATOCELLULAR-CARCINOMA; MICRORNAS; CANCER; RECOGNITION; SURVIVAL; RNA; ACTIVATION; APOPTOSIS; GENES; CELLS;
D O I
10.1016/j.febslet.2014.10.004
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Pancreatic ductal adenocarcinoma (PDAC) ranks fourth on the list of cancer-related causes of death. Deregulation or dysfunction of miRNAs contribute to cancer development. In this study, we found that low miR-545 level and high RIG-I protein in PDAC tissues were both correlated with low survival rate. MiR-545 up-regulation inhibited PDAC cell lines growth and vice versa. 3'UTR of RIG-I was targeted by miR-545. Thus we concluded that low miR-545 levels in PDAC promote tumor cells growth, and this is associated with reduced survival in PDAC patients. MiR-545 exerts its effects by directly targeting RIG-1. (C) 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:4375 / 4381
页数:7
相关论文
共 50 条
  • [31] Growth hormone receptor inhibition decreases the growth and metastasis of pancreatic ductal adenocarcinoma
    Subramani, Ramadevi
    Lopez-Valdez, Rebecca
    Salcido, Alyssa
    Boopalan, Thiyagarajan
    Arumugam, Arunkumar
    Nandy, Sushmita
    Lakshmanaswamy, Rajkumar
    EXPERIMENTAL AND MOLECULAR MEDICINE, 2014, 46 : e117 - e117
  • [32] Targeting Pancreatic Ductal Adenocarcinoma Acidic Microenvironment
    Cruz-Monserrate, Zobeida
    Roland, Christina L.
    Deng, Defeng
    Arumugam, Thiruvengadam
    Moshnikova, Anna
    Andreev, Oleg A.
    Reshetnyak, Yana K.
    Logsdon, Craig D.
    SCIENTIFIC REPORTS, 2014, 4
  • [33] Targeting hedgehog signaling in pancreatic ductal adenocarcinoma
    Quatannens, Delphine
    Verhoeven, Yannick
    Van Dam, Peter
    Lardon, Filip
    Prenen, Hans
    Roeyen, Geert
    Peeters, Marc
    Smits, Evelien L. J.
    Van Audenaerde, Jonas
    PHARMACOLOGY & THERAPEUTICS, 2022, 236
  • [34] Targeting hyaluronan for the treatment of pancreatic ductal adenocarcinoma
    Sato, Norihiro
    Cheng, Xiao-Bo
    Kohi, Shiro
    Koga, Atsuhiro
    Hirata, Keiji
    ACTA PHARMACEUTICA SINICA B, 2016, 6 (02) : 101 - 105
  • [35] Design, Synthesis, and Antitumor Evaluation of an Opioid Growth Factor Bioconjugate Targeting Pancreatic Ductal Adenocarcinoma
    Budka, Justyna
    Debowski, Dawid
    Mai, Shaoshan
    Narajczyk, Magdalena
    Hac, Stanislaw
    Rolka, Krzysztof
    Vrettos, Eirinaios I.
    Tzakos, Andreas G.
    Inkielewicz-Stepniak, Iwona
    PHARMACEUTICS, 2024, 16 (02)
  • [36] Targeting dendritic cells in pancreatic ductal adenocarcinoma
    Deicher, Anton
    Andersson, Roland
    Tingstedt, Bobby
    Lindell, Gert
    Bauden, Monika
    Ansari, Daniel
    CANCER CELL INTERNATIONAL, 2018, 18
  • [37] Targeting histone deacetylases in pancreatic ductal adenocarcinoma
    Schneider, Guenter
    Kraemer, Oliver H.
    Fritsche, Petra
    Schueler, Susanne
    Schmid, Roland M.
    Saur, Dieter
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2010, 14 (06) : 1255 - 1263
  • [38] CHID1 positively regulates RLR antiviral signaling by targeting the RIG-I/VISA signalosome
    Li, Sheng-Na
    Ling, Ting
    Yang, Ya-Xian
    Huang, Jing-Ping
    Xu, Liang-Guo
    JOURNAL OF MEDICAL VIROLOGY, 2019, 91 (09) : 1668 - 1678
  • [39] Targeting hyaluronan for the treatment of pancreatic ductal adenocarcinoma
    Norihiro Sato
    Xiao-Bo Cheng
    Shiro Kohi
    Atsuhiro Koga
    Keiji Hirata
    ActaPharmaceuticaSinicaB, 2016, 6 (02) : 101 - 105
  • [40] Effect of miR-184 on Proliferation and Apoptosis of Pancreatic Ductal Adenocarcinoma and Its Mechanism
    Li, Shentao
    Li, He
    Ge, Weiwei
    Song, Kai
    Yuan, Chunyu
    Yin, Ran
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2020, 19